109 related articles for article (PubMed ID: 3717188)
21. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods.
Zinner SH; Blaser J
J Antimicrob Chemother; 1986 Mar; 17 Suppl A():1-5. PubMed ID: 3086275
[TBL] [Abstract][Full Text] [Related]
22. [Comparative bactericidal activity of beta-lactam-aminoglycoside combinations against Pseudomonas aeruginosa].
Cluzel M; Chanal M; Sirot J; Cluzel R
Nouv Presse Med; 1982 Nov; 11(46):3400-4. PubMed ID: 6818523
[TBL] [Abstract][Full Text] [Related]
23. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
Knudsen JD
Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
[TBL] [Abstract][Full Text] [Related]
24. Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa.
Moriarty F; Elborn S; Tunney M
J Microbiol Methods; 2005 May; 61(2):171-9. PubMed ID: 15722142
[TBL] [Abstract][Full Text] [Related]
25. In vitro models for prediction of antimicrobial activity: a pharmacokinetic and pharmacodynamic perspective.
Li RC; Zhu ZY
J Chemother; 1997 May; 9 Suppl 1():55-63. PubMed ID: 9248963
[TBL] [Abstract][Full Text] [Related]
26. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Güzel CB; Gerçeker AA
Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363
[TBL] [Abstract][Full Text] [Related]
27. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
[TBL] [Abstract][Full Text] [Related]
28. 'Break-point Checkerboard Plate' for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa.
Tateda K; Ishii Y; Matsumoto T; Yamaguchi K
Scand J Infect Dis; 2006; 38(4):268-72. PubMed ID: 16709527
[TBL] [Abstract][Full Text] [Related]
29. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
Jarque I; Sanz MA
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
Philippon A
Chemioterapia; 1985 Dec; 4(6):424-8. PubMed ID: 3938346
[TBL] [Abstract][Full Text] [Related]
31. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains.
Rodríguez-Cerrato V; García P; Del Prado G; García E; Gracia M; Huelves L; Ponte C; López R; Soriano F
J Antimicrob Chemother; 2007 Nov; 60(5):1159-62. PubMed ID: 17827138
[TBL] [Abstract][Full Text] [Related]
32. [Optimization of antibiotics in combination].
Zhang LH; Wang LF; Meng ZY; Yu QP; Gao BQ; Ba T; Wang XD; Ma WH; Li YY; Zhang J
Zhonghua Shao Shang Za Zhi; 2008 Apr; 24(2):93-6. PubMed ID: 18785405
[TBL] [Abstract][Full Text] [Related]
33. Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.
Ulrich E; Trautmann M; Krause B; Bauernfeind A; Hahn H
Infection; 1989; 17(5):311-5. PubMed ID: 2599653
[TBL] [Abstract][Full Text] [Related]
34. Imipenem therapy of Pseudomonas aeruginosa bacteraemia in neutropenic rats.
Johnson DE; Calia FM; Snyder MJ; Warren JW; Schimpff SC
J Antimicrob Chemother; 1983 Dec; 12 Suppl D():89-96. PubMed ID: 6583199
[TBL] [Abstract][Full Text] [Related]
35. Use of an in-vitro kinetic model to study antibiotic combinations.
Zinner SH; Blaser J; Stone BB; Groner MC
J Antimicrob Chemother; 1985 Jan; 15 Suppl A():221-6. PubMed ID: 3920181
[TBL] [Abstract][Full Text] [Related]
36. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy.
Johnson MP; Ramphal R
J Infect Dis; 1990 Oct; 162(4):981-3. PubMed ID: 2205658
[TBL] [Abstract][Full Text] [Related]
37. Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis.
Chadwick EG; Shulman ST; Yogev R
J Infect Dis; 1986 Oct; 154(4):670-5. PubMed ID: 3528320
[TBL] [Abstract][Full Text] [Related]
38. Role of antimicrobial combinations in the therapy of infections in neutropenic patients.
Gialdroni Grassi G; Grassi C
Chemioterapia; 1987 Jun; 6(2 Suppl):398-400. PubMed ID: 3334582
[No Abstract] [Full Text] [Related]
39. Combined therapy with granulocyte transfusion, intravenous opsonins and antibiotics for overwhelming Pseudomonas aeruginosa septicemia in neutropenic cancer patients.
Engelhard D; Aker M; Or R; Shinar E
Pediatr Infect Dis J; 1989 May; 8(5):332-4. PubMed ID: 2471138
[No Abstract] [Full Text] [Related]
40. Evolution of antibiotic therapy for infection in neutropenic patients: studies at M. D. Anderson Hospital.
Bodey GP
Rev Infect Dis; 1989; 11 Suppl 7():S1582-90. PubMed ID: 2690296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
